Abstract
The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Current Cancer Therapy Reviews
Title:Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Volume: 11 Issue: 2
Author(s): Georgios Koukourakis, Georgios Zacharias and Aristides Petridis
Affiliation:
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Abstract: The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Export Options
About this article
Cite this article as:
Koukourakis Georgios, Zacharias Georgios and Petridis Aristides, Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203012
DOI https://dx.doi.org/10.2174/1573394711666151022203012 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy
Current Bioactive Compounds Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics LOH12CR1 is a Novel Tumor Suppressor Inhibiting Tumor Growth Through Deregulation of G1/S Checkpoint in Human Colorectal Carcinoma
Current Molecular Medicine MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Prospects of Utilizing Computational Techniques for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Editorial ( Thematic Issue: Diabetes and Cancer - Disease, Drugs or Deception?)
Current Drug Safety Transmembrane Protein 166 and its Significance
Protein & Peptide Letters The Redox Biology of Schistosome Parasites and Applications for Drug Development
Current Pharmaceutical Design Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Exploration of Chemical Space Based on 4-Anilinoquinazoline
Current Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions
Current Vascular Pharmacology